VYNE Therapeutics Inc. (VYNE) — Revenue
| Fiscal Year | Revenue | Change YoY |
|---|---|---|
| 2025 | $570.0K | +13.8% |
| 2024 | $501.0K | +18.2% |
| 2023 | $424.0K | -11.1% |
| 2022 | $477.0K | -48.8% |
| 2021 | $931.0K | -95.6% |
| 2020 | $20.99M | +4638.8% |
| 2019 | $443.0K | -87.7% |
| 2018 | $3.60M | — |
| Fiscal Year | Revenue | Change YoY |
|---|---|---|
| 2025 | $570.0K | +13.8% |
| 2024 | $501.0K | +18.2% |
| 2023 | $424.0K | -11.1% |
| 2022 | $477.0K | -48.8% |
| 2021 | $931.0K | -95.6% |
| 2020 | $20.99M | +4638.8% |
| 2019 | $443.0K | -87.7% |
| 2018 | $3.60M | — |